Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in California: - UCLA Hematology/Oncology - Alhambra — Alhambra, California
- UCLA Hematology/Oncology - Atascadero — Atascadero, California
- Cedars-Sinai Cancer Beverly Hills (drug treatment and dispensing location) — Beverly Hills, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- UCLA Hematology/Oncology - Beverly Hills — Beverly Hills, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in California: - UCLA Hematology/Oncology - Santa Monica ( Site 0044) — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center (0120) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Emad Ibrahim,MD,INC. ( Site 0012) — Redlands, California
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Sites in California: - Local Institution - 0370 — Anaheim, California
- Moores Cancer Center — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Local Institution - 0364 — Los Angeles, California
- California Pacific Medical Center — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in California: - University of California at San Diego — La Jolla, California
- Cedars Sinai Medical Center — Los Angeles, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in California: - City of Hope Comprehensive Cancer Center ( Site 0049) — Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0059) — Irvine, California
- Moores Cancer Center ( Site 0010) — La Jolla, California
- Veterans Affairs Long Beach Healthcare System ( Site 0058) — Long Beach, California
- Cedars-Sinai Medical Center ( Site 0068) — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in California: - MemorialCare Orange Coast Medical Center — Fountain Valley, California
- University Of California San Diego — La Jolla, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Kaiser Permanente Southern California — Riverside, California
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in California: - Los Angeles Cancer Network (LACN) — Anaheim, California
- Los Angeles Cancer Network (LACN) — Fountain Valley, California
- Los Angeles Cancer Network (LACN) — Glendale, California
- Los Angeles Cancer Network (LACN) — Glendale, California
- Los Angeles Cancer Network (LACN) — Laguna Hills, California
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in California: - University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in California: - Providence Medical Foundation — Fullerton, California
- Tower Urology — Los Angeles, California
- VA Greater Los Angeles Healthcare System — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- University of California, Irvine — Orange, California
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in California: - Research Site — La Jolla, California
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Diego, California
- Research Site — San Luis Obispo, California
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in California: - VA Greater LA Healthcare System — Los Angeles, California
- VA Palo Alto Health Care System — Palo Alto, California
- Stanford University Medical Center — Palo Alto, California
- Sansum Clinic — Santa Barbara, California
- Saint Johns Cancer Institute — Santa Monica, California
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in California: - Urology Group of Southern California — Los Angeles, California
- Greater Los Angeles VA Medical Center — Los Angeles, California
- UC Irvine Health — Orange, California
- Stanford University Medical Center — Stanford, California
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in California: - Research Site — Duarte, California
- Research Site — Irvine, California
- Research Site — Newport Beach, California
- Research Site — San Francisco, California
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in California: - VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the im…
Sponsor: University of Alberta
NCT ID: NCT06626022
Sites in California: - University of California, Los Angeles (UCLA) — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in California: - Enloe Medical Center — Chico, California
- UC San Diego Health System - Encinitas — Encinitas, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in California: - University of California, Los Angeles (UCLA) — Los Angeles, California
- Stanford Cancer Institute, Stanford University — Palo Alto, California
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Sarcoma Oncology Center — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in California: - Research Site 125 — Los Angeles, California
- Research Site 133 — Los Angeles, California
- Research Site 103 — Los Angeles, California
- Research Site 128 — Santa Monica, California
Phase 2 Recruiting Industry
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Sponsor: Syncromune, Inc.
NCT ID: NCT06533644
Sites in California: - University of California-Davis — Sacramento, California
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in California: - Cedars Sinai Medical Center — Los Angeles, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCSF Medical Center at Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in California: - MemorialCare Orange Coast Medical Center — Fountain Valley, California
- Cancer and Blood Research Center — Los Alamitos, California